The Trump Administration will be successful in finding solutions to high prescription drug pricing in part because it has enlisted individuals with biopharma industry experience to direct the development of policies, Office of Management and Budget Associate Director for Health Programs Joe Grogan told the Biopharma Congress in Washington, DC on Nov. 14.
Comparing the Trump Administration's approach to drug pricing with that in the Obama Administration, he predicted: "We're going to be...






